Anti-gastrointestinal cancer activity of cyclodextrin-encapsulated propolis. (February 2018)

• Record Type: Journal Article
• Authors: Catchpole, Owen; Mitchell, Kevin; Bloor, Stephen; Davis, Paul; Suddes, Amanda
• Is Part Of: Journal of functional foods. Volume 41(2018)
• Page Start: 1
• Page End: 8
• Publication Date: 2018-02
• Subjects: Propolis -- Cyclodextrin -- Cancer -- Gastrointestinal -- Encapsulated; Functional foods -- Analysis -- Periodicals; Food -- Biotechnology -- Periodicals; Nutrition -- Periodicals; 613.2
• DOI: 10.1016/j.jff.2017.12.023
• Languages: English
• ISSNs: 1756-4646

Abstract

Highlights: γCD was the most effective type of cyclodextrin for encapsulating New Zealand propolis. γ, α and βCD complexes inhibit the proliferation of 4 four human gastro-intestinal cancer cell lines. New Zealand propolis-γCD complexes strongly inhibit production of TNF-α. Abstract: New Zealand propolis resin and tinctures are rich in compounds that have in vitro anti-gastrointestinal cancer activity. However, propolis tincture has restricted acceptability for human consumption due to pungency in taste and aroma. We have formulated New Zealand propolis into cyclodextrin complexes (CD) that resolve these acceptability issues, and carried out in vitro bioactivity testing of these complexes using human anti-gastrointestinal cancer, anti-inflammatory and anti-oxidant assays. Demonstration of encapsulation was performed by physical, enzymic and chemical measurements. The New Zealand propolis γCD, αCD, and βCD complexes inhibited the proliferation of 4 human gastro-intestinal cancer cell lines, with the extent of inhibition increasing with increasing exposure time. The complexes were also strongly anti-inflammatory in vitro with respect to the cytokine TNF-α, and showed strong lipid anti-oxidant activity. The bioassay results give a strong first indication of beneficial gastro-intestinal health potential of New Zealand propolis – cyclodextrin complexes.